PETACH TIKVA, Israel--(BUSINESS WIRE)--Jan. 24, 2006--Can-Fite BioPharma (TASE:CFBI) announced today on the signing of a Cooperative Research and Development Agreement (CRADA) with the National Institute of Health in the U.S. The CRADA relates to new small molecules that are agonists of the A(3) adenosine receptor (A(3)AR), invented in the laboratory of Prof. Kenneth A. Jacobson from the NIH. The A(3)AR is the prime target of Can-Fite's drug development efforts. The focus of the CRADA will be to identify such agonists with potential therapeutic use in the treatment of autoimmune inflammatory diseases and cancer.
